Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > 2023 - The Road to Registration

<< Previous

Bullboard Posts

Next >>

Post by Probosciseson Mar 07, 2023 4:48pm

428 Views

Post# 35324586

2023 - The Road to Registration

In today's interview with Matt Coffey the graphic behind Matt said :

Oncolytics Biotech
Inc.

2023 - The Road to Registration

ONC/Y is emphasizing again and again that this is the time to move to registration trials. They are not shrinking violets. They are sending a message to pharma and all other stakeholders.

<< Previous

Bullboard Posts

Next >>

A Look into the Future of Chronic Pain Management